Kaisa Helminen
Chief Operating Officer at AIFORIA TECHNOLOGIES OYJ
Net worth: 599 790 $ as of 2024-04-29
Profile
Kaisa Helminen is currently the Chief Operating Officer at Aiforia Technologies Oyj since 2020.
Previously, she worked as a Product Manager at Finnzymes Oy from 2001 to 2011, at Thermo Fisher Scientific Oy from 2011 to 2012, and at Sartorius Biohit Liquid Handling Oy from 2012 to 2014.
Ms. Helminen is a graduate of the University of Helsinki.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-08-30 | 145,700 ( 0.56% ) | 599 790 $ | 2024-04-29 |
Kaisa Helminen active positions
Companies | Position | Start |
---|---|---|
AIFORIA TECHNOLOGIES OYJ | Chief Operating Officer | 2020-06-30 |
Former positions of Kaisa Helminen
Companies | Position | End |
---|---|---|
Sartorius Biohit Liquid Handling Oy
Sartorius Biohit Liquid Handling Oy Electronic Equipment/InstrumentsElectronic Technology Part of Sartorius AG, Sartorius Biohit Liquid Handling Oy manufactures measuring and controlling devices. The company is based in Helsinki, Finland. | Corporate Officer/Principal | 2014-05-31 |
Thermo Fisher Scientific Oy
Thermo Fisher Scientific Oy Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Thermo Fisher Scientific Oy is a Finnish company that manufactures and supplies medical and dental instruments. The company is based in Vanda, Finland. The CEO of the company is Timo Tapio Hildén. | Corporate Officer/Principal | 2012-04-30 |
Finnzymes Oy
Finnzymes Oy Pharmaceuticals: MajorHealth Technology The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Finnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise. | Corporate Officer/Principal | 2010-12-31 |
Training of Kaisa Helminen
University of Helsinki | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AIFORIA TECHNOLOGIES OYJ | Technology Services |
Private companies | 3 |
---|---|
Sartorius Biohit Liquid Handling Oy
Sartorius Biohit Liquid Handling Oy Electronic Equipment/InstrumentsElectronic Technology Part of Sartorius AG, Sartorius Biohit Liquid Handling Oy manufactures measuring and controlling devices. The company is based in Helsinki, Finland. | Electronic Technology |
Thermo Fisher Scientific Oy
Thermo Fisher Scientific Oy Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Thermo Fisher Scientific Oy is a Finnish company that manufactures and supplies medical and dental instruments. The company is based in Vanda, Finland. The CEO of the company is Timo Tapio Hildén. | Health Technology |
Finnzymes Oy
Finnzymes Oy Pharmaceuticals: MajorHealth Technology The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Finnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise. | Health Technology |
- Stock Market
- Insiders
- Kaisa Helminen